426 related articles for article (PubMed ID: 36455783)
21. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
[TBL] [Abstract][Full Text] [Related]
23. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
24. Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer.
Feng M; Wang F; Liu X; Hao T; Zhang N; Deng M; Pan Y; Kong R
Cancer Biol Med; 2023 May; 20(6):421-37. PubMed ID: 37184030
[TBL] [Abstract][Full Text] [Related]
25. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
26. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
[TBL] [Abstract][Full Text] [Related]
28. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma.
Yang W; Feng Y; Zhou J; Cheung OK; Cao J; Wang J; Tang W; Tu Y; Xu L; Wu F; Tan Z; Sun H; Tian Y; Wong J; Lai PB; Chan SL; Chan AW; Tan PB; Chen Z; Sung JJ; Yip KY; To KF; Cheng AS
Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827976
[TBL] [Abstract][Full Text] [Related]
29. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
31. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
32. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
33. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
Zhou C; Weng J; Liu C; Liu S; Hu Z; Xie X; Gao D; Zhou Q; Sun J; Xu R; Li H; Shen Y; Yi Y; Shi Y; Sheng X; Dong Q; Hung MC; Ren N
Gastroenterology; 2023 Jun; 164(7):1261-1278. PubMed ID: 36863689
[TBL] [Abstract][Full Text] [Related]
34. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
35. Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment.
Repáraz D; Casares N; Fuentes A; Navarro F
Methods Cell Biol; 2024; 185():79-97. PubMed ID: 38556453
[TBL] [Abstract][Full Text] [Related]
36. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
37. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
38. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
Xie P; Yu M; Zhang B; Yu Q; Zhao Y; Wu M; Jin L; Yan J; Zhou B; Liu S; Li X; Zhou C; Zhu X; Huang C; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Guo L; Li H
J Hepatol; 2024 Feb; ():. PubMed ID: 38403027
[TBL] [Abstract][Full Text] [Related]
39. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
Li X; Ding X; Li W; Chen J
Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
[TBL] [Abstract][Full Text] [Related]
40. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
